Answers are grounded in this paper and cite their sources.
Observational analysis finds that TME and TP53 status may predict immune checkpoint inhibitor success in NSCLC with EGFR mutations, implying treatment personalization.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Azuma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: